Trending in Longevity

Semaglutide and tirzepatide show longevity benefits beyond weight loss including inflammation reduction and cardiovascular protection. SELECT trial data driving massive research interest.

DNA methylation-based biological age tests like GrimAge and DunedinPACE now used to measure intervention efficacy in longevity trials. Consumer testing expanding rapidly.

mTOR inhibitor with robust preclinical longevity data; PEARL trial and off-label human use driving intense discussion. Multiple new trials launched in 2025-2026.

Yamanaka factor cycling to reverse cellular aging without inducing pluripotency. Altos Labs, Retro Biosciences, and others publishing key 2025-2026 results.

Drugs that selectively clear senescent cells showing human trial results for frailty and disease. Dasatinib+quercetin and fisetin dominate clinical pipeline.

Consumer and clinical biological age tests combining methylation, proteomics, and metabolomics surging. Companies like TruDiagnostic and Elysium expanding product lines.

NMN and nicotinamide riboside supplements targeting NAD+ decline with aging. Multiple human trials reporting muscle, metabolic, and cognitive benefits in 2025-2026.

OCT4, SOX2, KLF4, MYC gene expression driving age reversal research. In vivo delivery systems and safety profiles now center of intense biotech competition.

Mitophagy activator derived from pomegranate now in human trials for muscle aging and mitochondrial health. Amazentis/Timeline commercialization advancing rapidly.

Young plasma infusion and plasmapheresis to remove pro-aging blood factors gaining traction post-Conboy lab work. Several clinics now offering commercial protocols.

TAME trial (Targeting Aging with Metformin) results eagerly awaited. Metformin's AMPK activation and inflammation reduction make it a cornerstone geroscience drug.

BPC-157, TB-500, epitalon, and other peptides used off-label for tissue repair and longevity. Regulatory scrutiny increasing while biohacker adoption surges.

Leading senolytic combination with Mayo Clinic trials showing reduced senescent cell burden in humans. Now being tested for Alzheimer's, IPF, and diabetes complications.

Mitochondrial electron carrier showing neuroprotective and anti-aging properties in preclinical models. Biohacker adoption soaring with emerging human cognitive data.

Natural flavonoid with strong senolytic activity in preclinical models; Mayo Clinic human trials ongoing. Popular due to accessibility and favorable safety profile.

Valter Longo's ProLon 5-day fasting protocol showing reduced biological age markers in human trials. New IGF-1 and autophagy mechanistic data published 2025.

Cardiorespiratory fitness as strongest predictor of all-cause mortality. VO2 max testing and training protocols now standard in longevity medicine clinics.

Polyamine autophagy inducer found in aged cheese and wheat germ. Multiple human trials for cognitive aging and cardiovascular health reporting positive results in 2025-2026.

Glycine and N-acetylcysteine combination shown to improve multiple aging hallmarks in older humans in Baylor trials. Affordable and well-tolerated driving rapid adoption.

Compounds that suppress SASP without killing senescent cells. Emerging as complementary approach to senolytics with potentially better safety profiles for chronic use.

2023 Science paper showing taurine decline drives aging and supplementation extends lifespan in multiple species. Human clinical trials now underway following massive publicity.

Integration of genomics, proteomics, metabolomics, and epigenomics to build comprehensive aging profiles. Stanford and Buck Institute leading landmark studies.

TCA cycle intermediate and epigenetic regulator; CalerieHealth/Juvena trials show biological age reduction. Powerful intersection of metabolism and epigenetics.